FindTrial
Sign In

Nanatinostat

DRUG2 trials

Sponsors

Viracta Therapeutics Inc., Viracta Therapeutics Inc., Viracta Therapeutics, Inc.

Conditions

EBV Related CarcinomaEBV-Related Gastric CarcinomaEBV-Related LeiomyosarcomaEBV-Related SarcomaEpstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasNasopharyngeal Carcinoma

Phase 1

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
TerminatedNCT05166577
Viracta Therapeutics, Inc.EBV Related Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma +2
Start: 2021-10-08End: 2025-01-10Updated: 2025-03-12

Phase 2

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
CompletedCTIS2024-512717-41-00
Viracta Therapeutics Inc., Viracta Therapeutics Inc.Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Start: 2021-10-01End: 2024-12-26Target: 84Updated: 2024-09-05

Related Papers

156P A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in advanced Epstein-Barr virus positive (EBV+) solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC)
Immuno-Oncology Technology2022-12-011 citations
A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV<sup>+</sup>) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).
Journal of Clinical Oncology2022-06-012 citations